ArticleScientific reports2026
Docosahexaenoic acid is comparable to vildagliptin in improving hyperglycemia and pancreatic insulin signaling of diabetic rats via SIRT1/Akt/PI3K pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sirtuin1 (SIRT1) is a histone deacetylase that plays a critical role in insulin sensitivity. Vildagliptin (Vilda) is dipeptidyl peptidase-4 inhibitor approved as oral antidiabetic agent. Docosahexaenoic (DHA) could attenuate hyperglycemia and insulin resistance. The current study was conducted to evaluate the effect of DHA versus Vilda on insulin resistance and hyperglycemia in type 2 diabetes (T2D) rat model via SIRT1/Akt/PI3K. Eighty male Wistar rats were divided into five groups: normal control, diabetes control (the diabetic rats fed high carbohydrate-high fat diet for four weeks, followed by a single intraperitoneal injection of 35 mg/kg streptozotocin, Vilda + diabetic (diabetic rats received 6 mg/kg vildagliptin), DHA + diabetic (diabetic rats received 300 mg/kg DHA), and DHA only group (normal non-diabetic rats received 300 mg/kg DHA). All treatments were given orally for 4 weeks. Each of Vilda and DHA significantly (p < 0.001) decreased blood glucose (131.40. ± 6.10 mg/L and 137.10 ± 7.37, respectively vs. 449.9 ±46.28 1.84 mg/L), increased insulin levels (7.77 ±0.26 µIU/mL and 7.56 ± 0.42, respectively vs. 3.86 ± 0.37 ), decreased HOMA-IR (2.52 ± 0.09 and 2.55 ± 0.091, respectively vs. 4.26 ± 0.34), decreased pancreatic malondialdehyde (MDA) (3.84 ± 0.29 nmol/mg protein and 3.18 ± 0.21, respectively vs. 6.65 ± 0.71), increased gluthathione (2.18±0.11μmol/mg protein and 2.51±0.09, respectively vs. 1.00±0.29), catalase (104.50±6.74 nmol/mg protein and 122.30±6.20, respectively vs. 70.30±13.98), increased glutathione peroxidase activity (GPx) (0.76±0.19 U/mg protein and 0.99±0.16, respectively vs. 0.47± 0.14) and increased superoxide dismutase activity (SOD) (6.43±1.15 U/mg protein and 8.13±1.16, respectively vs. 3.98±1.4) compared with diabetic group. DHA & Vilda significantly (p < 0.001) improved lipid profile (total cholesterol, triglycerides, LDL-C & HDL-C). DHA was superior to Vilda in increasing levels of glutathione (2.51 ± 0.09 µmol/mg protein vs. 2.18 ± 0.11), catalase activity (122.30 ± 6.20 nmol/mg protein vs. 104.50 ± 6.74 ), SOD activity (8.13±1.16 U/mg vs. 6.43±1.15) and GPx activity (0.99±0.16 U/mg protein vs. 0.76±0.19). Moreover, both Vilda and DHA significantly increase gene expression of SIRT1, Akt, and PI3K and markedly restored normal pancreatic tissue architecture compared with diabetic control group. DHA was comparable to Vilda as insulinotropic and anti-hyperglycemic agent in T2D rats via activation of SIRT1/Akt/PI3K pathway & reducing oxidative stress.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.